ArticleNanotoxicology2016
Organ burden and pulmonary toxicity of nano-sized copper (II) oxide particles after short-term inhalation exposure.
Article in Nanotoxicology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 182 citations in OpenAlex.
- A Comprehensive Review on Copper Oxide Nanoparticles: Physicochemical Parameters, Pharmacological Potential and Pathophysiological Effects.International journal of nanomedicine · 2026Review
- Assessing Antibacterial Properties of Copper Oxide Nanomaterials on Gut-Relevant Bacteria In Vitro: A Multifaceted Approach.Nanomaterials (Basel, Switzerland) · 2025Article
- Multimodal feature fusion machine learning for predicting chronic injury induced by engineered nanomaterials.Nature communications · 2025Article
- Assessment and prediction of copper release amount from copper oxide facepieces.Frontiers in public health · 2025Article
- Oxide-Perovskites for Automotive Catalysts Biotransform and Induce Multicomponent Clearance and Hazard.ACS nano · 2024Article
- MMP-3 mediates copper oxide nanoparticle-induced pulmonary inflammation and fibrosis.Journal of nanobiotechnology · 2024Article
- Article
- Opportunities and Challenges for Inhalable Nanomedicine Formulations in Respiratory Diseases: A Review.International journal of nanomedicine · 2024Review
- Toxicity of Metal Oxide Nanoparticles: Looking through the Lens of Toxicogenomics.International journal of molecular sciences · 2023Article
- Roles of Nrf2/HO-1 and ICAM-1 in the Protective Effect of Nano-Curcumin against Copper-Induced Lung Injury.International journal of molecular sciences · 2023Article
- Immunomodulatory Effects of Subacute Inhalation Exposure to Copper Oxide Nanoparticles in House Dust Mite-Induced Asthma.ACS nano · 2023Article
- Identification of a Gene Signature Predicting (Nano)Particle-Induced Adverse Lung Outcome in Rats.International journal of molecular sciences · 2023Article
- Acute phase response following pulmonary exposure to soluble and insoluble metal oxide nanomaterials in mice.Particle and fibre toxicology · 2023Article
- Insights into nanoparticles-induced neurotoxicity and cope up strategies.Frontiers in neuroscience · 2023Review
- Comparison of In Vitro Approaches to Assess the Antibacterial Effects of Nanomaterials.Journal of functional biomaterials · 2022Article
- Pulmonary Toxicity and Proteomic Analysis in Bronchoalveolar Lavage Fluids and Lungs of Rats Exposed to Copper Oxide Nanoparticles.International journal of molecular sciences · 2022Article
- Time course of pulmonary inflammation and trace element biodistribution during and after sub-acute inhalation exposure to copper oxide nanoparticles in a murine model.Particle and fibre toxicology · 2022Article
- The High-Throughput In Vitro CometChip Assay for the Analysis of Metal Oxide Nanomaterial Induced DNA Damage.Nanomaterials (Basel, Switzerland) · 2022Article
- Copper oxide nanoparticles trigger macrophage cell death with misfolding of Cu/Zn superoxide dismutase 1 (SOD1).Particle and fibre toxicology · 2022Article
- Towards health-based nano reference values (HNRVs) for occupational exposure: Recommendations from an expert panel.NanoImpact · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIncreased use of nanomaterials has raised concerns about the potential for undesirable human health and environmental effects. Releases into the air may occur and, therefore, the inhalation route is of specific interest. Here we tested copper oxide nanoparticles (CuO NPs) after repeated inhalation as hazard data for this material and exposure route is currently lacking for risk assessment.
methodsRats were exposed nose-only to a single exposure concentration and by varying the exposure time, different dose levels were obtained (C × T protocol). The dose is expressed as 6 h-concentration equivalents of 0, 0.6, 2.4, 3.3, 6.3, and 13.2 mg/m(3) CuO NPs, with a primary particle size of 10 9.2-14 nm and an MMAD of 1.5 μm.
resultsTwenty-four hours after a 5-d exposure, dose-dependent lung inflammation and cytotoxicity were observed. Histopathological examinations indicated alveolitis, bronchiolitis, vacuolation of the respiratory epithelium, and emphysema in the lung starting at 2.4 mg/m(3). After a recovery period of 22 d, limited inflammation was still observed, but only at the highest dose of 13.2 mg/m(3). The olfactory epithelium in the nose degenerated 24 h after exposure to 6.3 and 13.2 mg/m(3), but this was restored after 22 d. No histopathological changes were detected in the brain, olfactory bulb, spleen, kidney and liver.
conclusionA 5-d, 6-h/day exposure equivalent to an aerosol of agglomerated CuO NPs resulted in a dose-dependent toxicity in rats, which almost completely resolved during a 3-week post-exposure period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.